Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06437353
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-05-26
Brief Title:
Surufatinib Combined With CarboplatinPaclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Sponsor:
Anhui Provincial Cancer Hospital
Organization:
Anhui Provincial Cancer Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-25
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-10-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-26
First Submit QC Date:
May 26 2024
Study First Post Date:
2024-05-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-21
Last Update Post Date:
2024-05-31
Last Update Post Date Type:
ACTUAL